NorthStar Medical Radioisotopes Sets New Industry Precedent in Advancing Non-uranium based Commercial Production of Molybdenum-99 (Mo-99)
Retrieved on:
Wednesday, January 11, 2023
Science, Radiology, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Other Health, Radiopharmaceutical, University of Missouri Research Reactor Center, Uranium, NorthStar, University, U.S. Department of Defense Strategy for Operating in Cyberspace, Isotope, Actinium-225, Senior, IBA, Patient, Graphite-moderated reactor, Multimedia, High energy, Technetium, Medical imaging
NorthStar’s proprietary electron accelerator technology has successfully produced Mo-99 at its recently completed Accelerator Production facility on its Beloit, Wis. campus.
Key Points:
- NorthStar’s proprietary electron accelerator technology has successfully produced Mo-99 at its recently completed Accelerator Production facility on its Beloit, Wis. campus.
- Like all NorthStar processes, it uses non-uranium based technology that is independent of reliance on overseas nuclear reactors.
- NorthStar’s technology produces far less radioactive waste than uranium-based Mo-99 production processes, which makes the NorthStar process more environmentally friendly.
- It enables increased Mo-99 production capability, greater scheduling flexibility and results in a benign and easily managed waste stream.”